BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesEarnings

SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today

Related news

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

TMCITreace Medical Concepts2026-08-07 11:05 EST

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

HYPRHyperfine2026-08-06 20:05 EST

Hyperfine, Inc. Reports Second Quarter 2026 Financial Results

ICUSeaStar Medical2026-08-06 12:35 EST

SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026

XTNTXtant Medical2026-08-06 12:00 EST

Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

NEPHNephros2026-08-05 20:00 EST

Nephros Schedules Second Quarter 2026 Financial Results Conference Call

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

ADPTAdaptive Biotechnologies2026-06-17 10:00 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-15 20:10 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Stock data

Close
23.60 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States